$STSN 1.1M float on alert! Article out today featuring

New Post Public Reply Private Reply Replies (0) Message Board
BCNstocks
178
$STSN 1.1M float on alert! Article out today featuring Stemsation >>

STSN: A Unique Approach to a $290B Market

Market participants looking for promising speculative small-cap opportunities with sizeable potential to make waves in large and growing addressable market opportunities may want to acquaint themselves with Stemsation International Inc (OTCMKTS:STSN).

According to its materials, the company develops, manufactures and distributes natural wellness products that support the stem cell and endocannabinoid systems in the human body through using a direct selling model in which Independent Wellness Advocates advertise and sell its products directly to consumers.

That last part is the key: this is a direct sales model in the nutraceutical wellness space – think: Avon or Amway, but with natural health products.

Shares of STSN have been on fire in the past 2-3 weeks, up as much as 350% at one point. That rally has consolidated and now pulled back in a seemingly constructive manner, with key moving averages now trailing and pointing higher and some important support levels in play.

The explosion off the lows looks to be about the company’s continued progress on establishing significant commercial stage operations and topline growth with the successful launch of its second major product, a fast-acting and exclusive formula named ProStem PSP for joint and muscle health, which is now reportedly in U.S. distribution and available for sale through the company’s network of Independent Wellness Advocates.

Pushing the Boundaries

To help press the narrative, the company also just made a critical announcement: Its products are now available in 30 markets (the 27 EU markets, the UK, the US and Puerto Rico). According to that release, the U.S. and European markets contribute $70 billion and $15 billion respectively to the $290 billion global market for nutraceuticals according to Fortune Business Insights.

StemSation is even accommodating the international hurdles, supporting online sales in multiple languages and at least four different currencies. StemSation even boasted that it has a customer service army ready to help with fluency in all of its serviced linguistic zones (English, Spanish, French and Bulgarian) and is apparently dead set on expanding into more linguistic zones.

Ray C. Carter, Jr., CEO of StemSation stated “we are pleased that we are now able to offer our products in multiple markets, languages and currencies through our online platform, during our very first year of business. We plan to enter even more markets in the second half of 2020 while adding at least two more languages and currencies. Our investment in a global infrastructure and localized, consumer-friendly support will bring us many loyal, long-term customers over time in this fast-growing global market, projected to reach $486 billion by 2026.”

All Around the World the Same Song

The key here is to understand that the direct sales model can work anywhere. People are people. Some people will want the products. Other people will want to make some extra money – especially in a world where we have seen over 40 million newly unemployed in the US alone over the past couple months.

Hence, STSN is clearly pushing to expand beyond the limitations of the US or North American market, and moving out to address the total market, which, according to the company is as large as $290 billion globally (for nutraceuticals)

Hence, there is a clear advantage to setting up that direct sales machine to be able to leap gracefully over currency and linguistic barriers to access more and more of the massive total addressable market.

$STSN
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 1

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Asia-Pacific Media Forum Eyes Future Growth Strategies

Updated Category News Views 2

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Continue Reading
Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Mermaid Folklore Meets Revolution in New Short Film

Updated Category News Views 2

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Ice-Rock Avalanches: Future Risks and Urgent Lessons

Updated Category News Views 1

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Aterian Prepares for Upcoming Earnings Call This Quarter

Updated Category News Views 99

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Continue Reading
Analyzing RTX: Trends in Short Interest and Market Sentiment

Updated Category News Views 176

Understanding RTX's Recent Market Movements RTX Corp has seen a notable shift in its market dynamics recently. The company's short interest, defined as the number of shares sold short but not yet covered, has decreased by 7.63% since the last reporting period. Currently, there are approximately 16.18 million shares sold short, equating to 1.21% of all shares available for...

Continue Reading
Celebrate Christmas Spirit with Personalized PrayerSongs

Updated Category News Views 156

Celebrate the Joy of Christmas with PrayerSong Bring Love Into Your Home with a PrayerSong for Your Family and Friends When the holiday season arrives, the focus shifts beyond material gifts. Instead, it’s about nurturing connections filled with love, faith, and meaningful moments. This Christmas, PrayerSong provides families with a unique opportunity to honor loved...

Continue Reading
Understanding the Short Selling Landscape of Analog Devices

Updated Category News Views 153

Analyzing Short Interest for Analog Devices As investors navigate the ever-changing stock market, understanding short interest can provide valuable insights into market sentiment regarding Analog Devices (NYSE: ADI). Recently, it was reported that Analog Devices has seen a notable increase of 4.11% in its short percent of float. Currently, there are approximately 7.52...

Continue Reading
Future of Clinical Trials: Exploring Market Growth to USD 85.37 Billion

Updated Category News Views 71

Understanding Clinical Trials and Their Importance Clinical trials serve as a fundamental pillar in advancing medical knowledge and enhancing patient care. These trials encompass a detailed and thorough process involving participant recruitment, intervention administration, data collection, and result analysis. The outcomes produced from clinical trials play a crucial...

Continue Reading